Jared M. Whitson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jared M. Whitson has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Maxwell V. Meng
5 shared publicationsAdam C. Reese
3 shared publicationsPeter R. Carroll
3 shared publicationsSima P. Porten
3 shared publications- Badrinath R. Konety
University of California San Francisco
2 shared publications G. Bennett Stackhouse
Department of Urology, University of California San Francisco, San Francisco, USA
2 shared publications
Latest Publications
- 1 May 2013
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 31 (4) , 442-447
Factors associated with downgrading in patients with high grade prostate cancer
- 1 May 2013
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 31 (4) , 442-447
Factors associated with downgrading in patients with high grade prostate cancer
- 1 February 2013
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 31 (2) , 259-263
Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus
- 1 February 2013
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 31 (2) , 259-263
Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus
- 18 May 2012
- Published by Springer Nature
- p. 187-199
The Future of Active Surveillance
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (5) , 1615-1620
Lymphadenectomy Improves Survival of Patients With Renal Cell Carcinoma and Nodal Metastases
In a population based cohort we determined whether an increase in the number of lymph nodes removed is associated with improved disease specific survival of patients with renal cell carcinoma treated with nephrectomy. Patients in the Surveillance, Epidemiology and End Results database with renal cell carcinoma and no evidence of distant metastases were identified. Those patients included in the study underwent radical or partial nephrectomy with lymphadenectomy. Cox regression analyses were performed to identify factors associated with disease specific survival including an interaction between lymph node status and the number of lymph nodes removed. Between 1988 and 2006, 9,586 patients with renal cell carcinoma met the study inclusion criteria. Median followup was 3.5 years (range 1.4 to 6.8). Of the patients 2,382 (25%) died of renal cell carcinoma, including 1,646 (20%) with lymph node negative disease and 736 (58%) with lymph node positive disease. There was no effect on disease specific survival with increasing the extent of lymphadenectomy in patients with negative lymph nodes (HR 1.0, 95% CI 0.9-1.1, p = 0.93). However, patients with positive lymph nodes had increased disease specific survival with extent of lymphadenectomy (HR 0.8 per 10 lymph nodes removed, 95% CI 0.7-1.0, p = 0.04). An increase of 10 lymph nodes in a patient with 1 positive lymph node was associated with a 10% absolute increase in disease specific survival at 5 years (p = 0.004). This study shows an association between increased lymph node yield and improved disease specific survival of patients with lymph node positive nonmetastatic renal cell carcinoma who underwent lymphadenectomy. Patients at high risk for nodal disease should be considered for regional or extended lymphadenectomy. Clinical variables to predict risk and validation of dissection templates are important areas for future research.
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (5) , 1615-1620
Lymphadenectomy Improves Survival of Patients With Renal Cell Carcinoma and Nodal Metastases
In a population based cohort we determined whether an increase in the number of lymph nodes removed is associated with improved disease specific survival of patients with renal cell carcinoma treated with nephrectomy. Patients in the Surveillance, Epidemiology and End Results database with renal cell carcinoma and no evidence of distant metastases were identified. Those patients included in the study underwent radical or partial nephrectomy with lymphadenectomy. Cox regression analyses were performed to identify factors associated with disease specific survival including an interaction between lymph node status and the number of lymph nodes removed. Between 1988 and 2006, 9,586 patients with renal cell carcinoma met the study inclusion criteria. Median followup was 3.5 years (range 1.4 to 6.8). Of the patients 2,382 (25%) died of renal cell carcinoma, including 1,646 (20%) with lymph node negative disease and 736 (58%) with lymph node positive disease. There was no effect on disease specific survival with increasing the extent of lymphadenectomy in patients with negative lymph nodes (HR 1.0, 95% CI 0.9-1.1, p = 0.93). However, patients with positive lymph nodes had increased disease specific survival with extent of lymphadenectomy (HR 0.8 per 10 lymph nodes removed, 95% CI 0.7-1.0, p = 0.04). An increase of 10 lymph nodes in a patient with 1 positive lymph node was associated with a 10% absolute increase in disease specific survival at 5 years (p = 0.004). This study shows an association between increased lymph node yield and improved disease specific survival of patients with lymph node positive nonmetastatic renal cell carcinoma who underwent lymphadenectomy. Patients at high risk for nodal disease should be considered for regional or extended lymphadenectomy. Clinical variables to predict risk and validation of dissection templates are important areas for future research.
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (5) , 1656-1660
The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer
We assessed whether an association exists between a change in prostate specific antigen and biopsy progression in men on active surveillance. A cohort of patients undergoing active surveillance for prostate cancer was identified from the urological oncology database at our institution. Multivariate logistic regression was performed to determine whether prostate specific antigen velocity, defined as the change in ln(prostate specific antigen) per year, is associated with biopsy progression, defined as a Gleason upgrade or volume progression on repeat biopsy within 24 months of diagnosis. A total of 241 men with a mean ± SD age of 61 ± 7 years and mean prostate specific antigen 4.9 ± 2.2 ng/ml met study inclusion criteria. Median time to repeat biopsy was 10 months (IQR 6-13). Biopsy progression developed in 55 men (23%), including a Gleason score upgrade in 46 (19%), greater than 33% positive cores in 11 (5%) and greater than 50% maximum single core positive in 12 (5%). The median prostate specific antigen ratio per year was 1.0 (IQR 0.95-1.03), although 1 man had a ratio of greater than 1.26 (doubled over 3 years) and 7 had a ratio of less than 1/1.26 (halved over 3 years). On multivariate analysis prostate specific antigen doubling within 3 years was associated with a 1.4-fold increase in the odds of biopsy progression (OR 1.4, 95% CI 0.6-3.4, p = 0.46). There is little change in prostate specific antigen during the first 24 months of surveillance in men with well staged, low risk prostate cancer. We believe that these findings highlight the importance of repeat biopsy during surveillance.
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (5) , 1656-1660
The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer
We assessed whether an association exists between a change in prostate specific antigen and biopsy progression in men on active surveillance. A cohort of patients undergoing active surveillance for prostate cancer was identified from the urological oncology database at our institution. Multivariate logistic regression was performed to determine whether prostate specific antigen velocity, defined as the change in ln(prostate specific antigen) per year, is associated with biopsy progression, defined as a Gleason upgrade or volume progression on repeat biopsy within 24 months of diagnosis. A total of 241 men with a mean ± SD age of 61 ± 7 years and mean prostate specific antigen 4.9 ± 2.2 ng/ml met study inclusion criteria. Median time to repeat biopsy was 10 months (IQR 6-13). Biopsy progression developed in 55 men (23%), including a Gleason score upgrade in 46 (19%), greater than 33% positive cores in 11 (5%) and greater than 50% maximum single core positive in 12 (5%). The median prostate specific antigen ratio per year was 1.0 (IQR 0.95-1.03), although 1 man had a ratio of greater than 1.26 (doubled over 3 years) and 7 had a ratio of less than 1/1.26 (halved over 3 years). On multivariate analysis prostate specific antigen doubling within 3 years was associated with a 1.4-fold increase in the odds of biopsy progression (OR 1.4, 95% CI 0.6-3.4, p = 0.46). There is little change in prostate specific antigen during the first 24 months of surveillance in men with well staged, low risk prostate cancer. We believe that these findings highlight the importance of repeat biopsy during surveillance.
- 8 February 2011
- Published by Springer Nature in Nature Reviews Urology
- Vol. 8 (3) , 124-125
Reducing overtreatment: active surveillance in low-risk disease
- 8 February 2011
- Published by Springer Nature in Nature Reviews Urology
- Vol. 8 (3) , 124-125
Reducing overtreatment: active surveillance in low-risk disease
- Open Access
- 29 September 2010
- Published by Wiley in BJU International
- Vol. 107 (5) , 729-734
Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? This is the first published report which is an in‐depth analysis of factors associated with surgery versus non‐operative management in patients with renal cell carcinoma and venous tumour thrombus. OBJECTIVE: • Venous tumour thrombus is common in patients with renal cell carcinoma (RCC). Although surgical morbidity has decreased with time, nephrectomy with caval thrombectomy remains a high‐risk procedure and may not be performed in all patients with this condition. Little is known about the factors influencing the decision to pursue surgery versus conservative management in patients with RCC and venous tumour thrombus. MATERIALS AND METHODS: • The Surveillance, Epidemiology, and End Results database was used to identify study patients with RCC and venous tumour thrombus. • Multiple clinical, pathological and sociodemographic variables were assessed. • Univariable and multivariable logistic regression analysis was performed to identify factors associated with surgery. RESULTS: • We identified 24 396 patients with RCC, of which 2265 (9.3%) had venous tumour thrombus. • Distant metastases (odds ratio [OR] 0.1, 95% CI 0.0–0.1), clinical stage T3c (OR 0.3, 95% CI 0.2–0.6), lymph node involvement (OR 0.4, 95% CI 0.2–0.6), being single (OR 0.4, 95% CI 0.3–0.7), and the age categories 61–70 years (OR 0.4, 95% CI 0.2–0.8, P = 0.01), 71–80 years (OR 0.2, 95% CI 0.1–0.3, P < 0.001), and ≥80 years (OR 0.1, 95% CI 0.0–0.1, P < 0.001) were significantly associated with non‐surgical management. CONCLUSIONS: • In this population‐based study, over 80% of patients with RCC and venous tumour thrombus underwent surgical management. • Although age and TNM stage were strongly associated with the decision to undergo surgery, marital status was also associated with treatment choice. • It is unclear whether marital status affects oncological outcomes or complication rates so the reasons behind this association deserve further investigation.
- 29 September 2010
- Published by Wiley in BJU International
- Vol. 107 (5) , 729-734
Open AccessFactors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? This is the first published report which is an in‐depth analysis of factors associated with surgery versus non‐operative management in patients with renal cell carcinoma and venous tumour thrombus. OBJECTIVE: • Venous tumour thrombus is common in patients with renal cell carcinoma (RCC). Although surgical morbidity has decreased with time, nephrectomy with caval thrombectomy remains a high‐risk procedure and may not be performed in all patients with this condition. Little is known about the factors influencing the decision to pursue surgery versus conservative management in patients with RCC and venous tumour thrombus. MATERIALS AND METHODS: • The Surveillance, Epidemiology, and End Results database was used to identify study patients with RCC and venous tumour thrombus. • Multiple clinical, pathological and sociodemographic variables were assessed. • Univariable and multivariable logistic regression analysis was performed to identify factors associated with surgery. RESULTS: • We identified 24 396 patients with RCC, of which 2265 (9.3%) had venous tumour thrombus. • Distant metastases (odds ratio [OR] 0.1, 95% CI 0.0–0.1), clinical stage T3c (OR 0.3, 95% CI 0.2–0.6), lymph node involvement (OR 0.4, 95% CI 0.2–0.6), being single (OR 0.4, 95% CI 0.3–0.7), and the age categories 61–70 years (OR 0.4, 95% CI 0.2–0.8, P = 0.01), 71–80 years (OR 0.2, 95% CI 0.1–0.3, P < 0.001), and ≥80 years (OR 0.1, 95% CI 0.0–0.1, P < 0.001) were significantly associated with non‐surgical management. CONCLUSIONS: • In this population‐based study, over 80% of patients with RCC and venous tumour thrombus underwent surgical management. • Although age and TNM stage were strongly associated with the decision to undergo surgery, marital status was also associated with treatment choice. • It is unclear whether marital status affects oncological outcomes or complication rates so the reasons behind this association deserve further investigation.
- Open Access
- 1 December 2009
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 35 (6) , 664-672
Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer
Purpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion™ analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion™ test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion™ of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion™ testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion™ following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia
- 1 December 2009
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 35 (6) , 664-672
Open AccessUrovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer
Purpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion™ analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion™ test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion™ of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion™ testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion™ following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia
- 9 July 2009
- Published by Wiley in BJU International
- Vol. 104 (3) , 336-339
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy
OBJECTIVE: To determine whether a multicolour fluorescence in situ hybridization test (UroVysion TM , Abbott Molecular Inc., Des Plaines, IL, USA) in patients with high‐risk superficial bladder tumours maintains its predictive ability in a multivariate model for recurrence and progression, incorporating clinical and pathological predictors of outcome. PATIENTS AND METHODS: The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively. UroVysion testing was used at the beginning and end of each IVT cycle, and cytology and cystoscopy 6 weeks after completing each cycle. Kaplan‐Meier actuarial survival was analysed, stratified by the UroVysion result after IVT. Univariate and multivariate Cox regression analyses were used to identify significant predictors of recurrence. RESULTS: In all, 42 patients had induction IVT with bacille Calmette‐Guérin (BCG), BCG + interferon, or mitomycin. The median follow‐up was 21 months. Recurrent disease was detected in 18 patients. In a univariate analysis, chronic renal insufficiency (hazard ratio 12.1, P = 0.03), positive cytology after IVT (2.7, P = 0.05), and a positive UroVysion test after IVT (8.3, P < 0.01) were predictive of failure. In the multivariate analysis, high grade disease (5.3, P = 0.05), a risk score of >6 (4.7, P = 0.02) and a positive UroVysion test after IVT (6.7, P < 0.01) were significant predictors of recurrence. CONCLUSION: In patients with high‐risk superficial bladder tumours undergoing IVT, a positive UroVysion test after treatment is highly predictive of recurrence, even in a multivariate model. Additional adjuvant therapy might be necessary in these patients to improve the outcome.
- 9 July 2009
- Published by Wiley in BJU International
- Vol. 104 (3) , 336-339
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy
OBJECTIVE: To determine whether a multicolour fluorescence in situ hybridization test (UroVysion TM , Abbott Molecular Inc., Des Plaines, IL, USA) in patients with high‐risk superficial bladder tumours maintains its predictive ability in a multivariate model for recurrence and progression, incorporating clinical and pathological predictors of outcome. PATIENTS AND METHODS: The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively. UroVysion testing was used at the beginning and end of each IVT cycle, and cytology and cystoscopy 6 weeks after completing each cycle. Kaplan‐Meier actuarial survival was analysed, stratified by the UroVysion result after IVT. Univariate and multivariate Cox regression analyses were used to identify significant predictors of recurrence. RESULTS: In all, 42 patients had induction IVT with bacille Calmette‐Guérin (BCG), BCG + interferon, or mitomycin. The median follow‐up was 21 months. Recurrent disease was detected in 18 patients. In a univariate analysis, chronic renal insufficiency (hazard ratio 12.1, P = 0.03), positive cytology after IVT (2.7, P = 0.05), and a positive UroVysion test after IVT (8.3, P < 0.01) were predictive of failure. In the multivariate analysis, high grade disease (5.3, P = 0.05), a risk score of >6 (4.7, P = 0.02) and a positive UroVysion test after IVT (6.7, P < 0.01) were significant predictors of recurrence. CONCLUSION: In patients with high‐risk superficial bladder tumours undergoing IVT, a positive UroVysion test after treatment is highly predictive of recurrence, even in a multivariate model. Additional adjuvant therapy might be necessary in these patients to improve the outcome.